Oculis
study overview | Oculis
Company
Deck Type
Deck date
July 2023
Slide
43 of 76
Related slides by other companies
ATAI
Investor Presentation
January 2024
core study weeks phase a is an open label in patients | ATAI
ATAI
Investor Presentation
October 2022
was well tolerated with no dose limiting toxicities identified up to the highest dose of given every hours for days there were no serious adverse events reported nor discontinuations due to adverse events and both single and multiple ascending dose sad and mad regimens showed only mild adverse events that were comparable to placebo treated subjects no evidence of sedation or other side effects at any doses tested dose dependent increase in frontal beta power was demonstrated in subjects receiving but not with placebo providing evidence of target engagement and mechanism of action these results show potential use for as a clinically superior treatment for generalized anxiety disorder gad compared to and combination pharmacodynamic effect along lower incidence severity shows favorable profile | ATAI
ATAI
Investor Presentation
October 2022
phase a efficacy data symbol coding category fluency data confirmed activity in schizophrenia population improved dose dependent widespread changes observed across brain regions symbol coding day day increased alpha middle high doses decreased beta dose observed elevations in resting state alpha increased and decreased suggesting a relaxed wakeful state without drowsiness at the mid to high dose levels has previously shown pro cognitive effects human clinical studies study showed wide spread beneficial | ATAI
Axcella Health
Results
September 2022
phase clinical trial underway interim analysis when subjects arm reached week | Axcella Health
Other recent decks by Oculis
See all presentations (7 decks)
Investor Presentation
April 2024
Results
August 2023
Investor Conference
June 2023
Results
May 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights